We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Detection of Subclinical Atherosclerosis in Asymptomatic Individuals (Decide CTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00862056
Recruitment Status : Completed
First Posted : March 16, 2009
Last Update Posted : November 20, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study will evaluate the use of cardiac CT in identifying atherosclerosis plaque in patients who have not been diagnosed with atherosclerosis and who have no symptoms of the disease but who are at risk of developing atherosclerosis based on traditional risk factors such as diabetes or a family history of coronary artery disease.

Condition or disease Intervention/treatment
Coronary Artery Disease Procedure: Cardiac CT

Study Design

Study Type : Observational
Actual Enrollment : 73 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Detection of Subclinical Atherosclerosis in Asymptomatic Individuals With High Likelihood of Coronary Artery Disease With a Novel, Low-Radiation Volumetric Computed Tomography Approach
Actual Study Start Date : January 2009
Primary Completion Date : July 2013
Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
Cardiac CT
All participants will undergo a coronary artery CT angiogram
Procedure: Cardiac CT
All participants will undergo a coronary artery CT angiogram with contrast.

Outcome Measures

Primary Outcome Measures :
  1. The primary endpoint of the study is identifying the prevalence of coronary artery disease (CAD) in an asymptomatic population of patients without prior history of, but with high likelihood of CAD. [ Time Frame: 6 months, 1 year ]

Biospecimen Retention:   Samples With DNA
Whole blood for DNA and RNA analysis for genetics and genomics

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Coronary Artery Disease

Inclusion Criteria:

  • Males between ages 35-90 or females between ages 40-90
  • No known coronary artery disease

    • no prior coronary disease by cardiac catheterization (no more than 40% in any major epicardial vessel)
    • no prior myocardial infarction
    • no prior ST-elevation myocardial infarction (1 mm ST-elevation in 2 contiguous leads)
    • no prior non-ST-elevation myocardial infarction (CK-MB > 2x ULN or elevated troponin that is indicative of myocardial necrosis based on local institutional cutpoints)
    • no prior coronary revascularization procedure
  • Aymptomatic

    • no chest pain, shortness of breath, angina or angina-equivalent that is assumed to be related to myocardial ischemia
  • Presence of a high-risk feature (at least one of the following four will quality)

    • High FRS ≥20% (http://hp2010.nhlbihin.net/atpiii/calculator.asp)
    • Diabetes Mellitus
    • Premature CAD in a first-degree relative
    • High Risk Lipid Profile (must meet one of the following laboratory criteria)

      1. LDL > 250 mg/dL
      2. HDL < 20 mg/dL
      3. Triglycerides > 1000 mg/dL
      4. LP(a) > 80 mg/dL
  • Provide written informed consent and Authorization for Use/Disclosure of PHI

Exclusion Criteria:

  • Known genetic form of hypercholesterolemia based on clinical criteria (e.g. familial hypercholesterolemia, etc.)
  • Creatinine 1.5 mg/dL or greater
  • Irregular rhythm precluding cardiac CT examination
  • Uncontrolled hypertension (SBP>210 mmHg or DBP>140 mmHg on treatment)
  • Known moderate or severe allergy to iodine-based contrast agents (mild prior reactions that could be treated as an outpatient or that could be prevented by pre-medication in the past do not constitute exclusion)
  • Known Pregnancy
  • Unwilling or unable to consent
  • Presence of any co-morbidity that makes life expectancy less than 24 months
  • Unwilling or unable to complete follow-up
  • Unwilling or unable to provide written informed consent and Authorization for Use/Disclosure of PHI
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00862056

United States, Georgia
Piedmont Hospital
Atlanta, Georgia, United States, 30309
Sponsors and Collaborators
Piedmont Healthcare
Principal Investigator: Sarah Rinehart, MD Piedmont Healthcare
More Information

Responsible Party: Piedmont Healthcare
ClinicalTrials.gov Identifier: NCT00862056     History of Changes
Other Study ID Numbers: PH08012
First Posted: March 16, 2009    Key Record Dates
Last Update Posted: November 20, 2017
Last Verified: November 2017

Keywords provided by Piedmont Healthcare:
coronary artery disease

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases